With an overwhelming majority, an independent advisory committee under the US drug agency FDA has found that Novo Nordisk’s Leader study provides substantial evidence of cardiovascular risk reduction in treatment with Victoza. The result opens up the opportunity for including the data on the product’s US label.
Zealand Pharma sees a significant potential for the candidate drug glepaglutide for treatment of short bowel syndrome (SBS), which has just delivered promising phase II results. The biotech company plans to win approval and market the drug on its own, hoping it can compete with a similar product from Shire, says CEO Britt Meelby Jensen.
Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.
The French-Danish biotech company Onxeo has raised EUR 15 million (USD 16.73 million) in a recently completed capital increase. The goal was EUR 12 million (USD 13.39 million), but the fundraising brought the company’s management a pleasant surprise.
The Danish dermatology company Leo Pharma has pumped money into a US based biotech company developing a medical device mainly to be used in treatments of a hair loss disease. It is also the first agreement made from Leo’s newly founded hub in Boston.
In a study with children at risk of developing type 1 diabetes, an experimental vaccine from Sweden's Diamyd Medical has failed to show a significant difference from placebo. The result cut off more than 20 percent of the company’s share price in just two days.
Swiss drug group Helsinn has returned the rights to a Zealand-developed drug to the Danish company and thus, cancelled an almost nine year old license agreement. However, Zealand’s CEO Britt Meelby Jensen is far from pessimistic.
Detailed data from Novo Nordisk’s comparative Devote study confirms that the company’s new insulin is as safe as and markedly more effective than its rival, the top-selling Lantus from Sanofi. This information can strengthen Novo’s position in the important ongoing negotiations with US payers.
The Danish biotech company Y-mAbs has yet again received a special designation from the US drug agency FDA for the company’s main candidate, which is being developed against a deadly type of brain cancer known as neuroblastoma.
Novo Nordisk has recruited a former AbbVie manager to lead the company’s European department, which has recently moved from Switzerland to Copenhagen. It is simply cheaper to have the 50 man unit in the Danish capital and according to CEO Lars Fruergaard Jørgensen, it is one of the world’s most attractive cities.
Allergy drug group ALK wants to be more than just a niche company in the immunotherapy field. Thus, 50 employees are now working on a new strategy for how the company can expand and become “a real allergy company” with a broader focus, says CEO Carsten Hellmann.
Novo Nordisk does not only aim to treat obesity, but also potentially to prevent it. The strategy could lead to new types of partnerships, for instance with the food industry, says CEO Lars Fruergaard Jørgensen.
Novo Nordisk has sold an experimental cancer drug in a deal that could earn the Danish company more than EUR 400 million. The deal sees Novo Nordisk raising its stake in the buyer, France's Innate Pharma.
During the span of a week, William Demant Invest has invested more than DKK 200 million (USD 30.16 million) in the Icelandic rehab company Össur. It is a common vote of confidence, says the investment company’s CEO Niels Jacobsen.
If the European Medicines Agency (EMA) moves to Denmark, the Danish government has a location lined up. But negotiations are omngoing and the Government is keeping its options open, says its special envoy, Lars Rebien Sørensen.
Novo Nordisk has submitted an application to the FDA, which will differentiate the company's insulin hope Tresiba from other basal insulins on the market and put it “in a league of its own”, says chief science officer Mads Krogsgaard Thomsen.
A small Danish diagnostics company, spun out from the Technical University of Denmark (DTU), is currently developing a rapid and easy blood test of viruses like Zika and Dengue. And the progress is so good that the product, by all accounts, will be ready for the market next year.
Novo A/S has stopped renting offices and instead bought the whole domicile in Hellerup from the pension fund PKA in order to avoid future space problems. The building was sold for a price of about USD 30 million above the official valuation.
Earlier this year, Novo Ventures participated in the IPO of a French company, among others developing drugs against the liver disease NASH. The same company now appoints principal of Novo Ventures Nanna Lüneborg to its executive board.
William Demant Invest, a part of the Oticon Foundation, has bought shares for more than DKK 100 million (USD 15 million) in the Icelandic prosthetics manufacturer Össur and thus, increased its ownership of the company.
A reward of DKK 10,000 (about USD 1,500) for employees recruiting new workers has been a success for the Danish hearing device giant William Demant – a success so great that the company now chooses to continue with the system.
Genmab’s CEO is ecstatic over the biotech's “shining star”, bone marrow cancer drug Darzalex. He doubts he will see anything like it in his time in the company, but is working intently on finding a new cash cow.
Norway-based financial services group DNB believes the Oslo Cancer Cluster has developed into one of Europe’s top biotech hubs. Norway’s life science industry is generally speaking more mature than a few years ago, says the group’s senior advisor for healthcare.
The global hearing device industry is currently benefitting from an ageing population. But what is going to drive growth when the demographic trend is reversed? MedWatch spoke to the Danish industry majors about the issue.